为30-39岁的一般人口提供乳腺癌风险评估的可行性和可接受性:一种混合方法研究协议
Sarah Hindmarch1, Sacha J Howell2, Juliet A Usher-Smith3
1Manchester Centre for Health Psychology, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK sarah.hindmarch@manchester.ac.uk.
BMJ open
|January 10, 2024
概括
30-39岁女性的乳腺癌风险评估正在BCAN-RAY研究中进行评估. 该策略结合了风险因素,乳房检查和多基因风险,以识别高风险个体,以便更早地进行干预.
科学领域:
- 在瘤学瘤学.
- 预防医学 预防医学
- 遗传学 遗传学 是一个
背景情况:
- 在30-39岁的女性中,乳腺癌发病率显著上升,在标准查资格之前.
- 目前的风险评估主要依赖于家族病史,可能缺失的高风险个体.
- 早期风险评估可以实现及时查和预防策略.
研究的目的:
- 为30-39岁的女性评估一个全面的乳腺癌风险评估策略.
- 评估年轻女性乳腺癌风险评估 (BCAN-RAY) 战略的可行性和可接受性.
- 为了比较跨社会经济地位和种族的吸收率.
主要方法:
- 病例控制研究涉及750名30-39岁没有强烈家族病史的女性.
- 使用风险因素调查问卷,乳腺密度低剂量乳房造影和多基因风险评估.
- 评估心理影响 (焦虑,担忧) 和决策满意度.
- 与子样本进行半结构面试,以完善策略.
主要成果:
- 参与者和非参与者之间的吸收率将根据社会经济地位和种族而进行比较.
- 心理影响,包括焦虑和癌症担忧,将被量化.
- 将测量参与者对决策过程的满意度.
结论:
- 该BCAN-RAY研究旨在建立一个可行和可接受的风险评估策略,针对年轻女性.
- 结果将为早期乳腺癌检测和预防计划的实施提供信息.
- 这项研究可以改善在预查年龄组中早期识别乳腺癌风险.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353


